联合方案-话题@MedSci

#联合方案#

18篇内容 | 1032人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1971909, encodeId=01e319e190934, content=<a href='/topic/show?id=f9c480e0860' target=_blank style='color:#2F92EE;'>#联合方案#</a>, objectTitle=速览奥希耐药治疗策略和结果，几大联合方案不如专注新疗法？, objectType=article, longId=732495, objectId=427be324952a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=427be324952a, replyNumber=0, likeNumber=63, createdTime=2022-07-24, rootId=0, userName=mashirong, userId=f13d475, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=427be324952a, moduleTitle=速览奥希耐药治疗策略和结果，几大联合方案不如专注新疗法？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=427be324952a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1971908, encodeId=87da19e1908e7, content=<a href='/topic/show?id=f9c480e0860' target=_blank style='color:#2F92EE;'>#联合方案#</a>, objectTitle=Clin Cancer Res：帕博西尼+氟维司群联合方案或可成为晚期乳腺癌的标准疗法, objectType=article, longId=730360, objectId=9feee303606b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9feee303606b, replyNumber=0, likeNumber=144, createdTime=2022-11-04, rootId=0, userName=mashirong, userId=f13d475, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9feee303606b, moduleTitle=Clin Cancer Res：帕博西尼+氟维司群联合方案或可成为晚期乳腺癌的标准疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9feee303606b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1971907, encodeId=7b3619e19074b, content=<a href='/topic/show?id=f9c480e0860' target=_blank style='color:#2F92EE;'>#联合方案#</a>, objectTitle=BMC Cancer：评估每周低剂量贝伐珠单抗联合方案治疗铂耐药卵巢癌患者的疗效, objectType=article, longId=299129, objectId=bdd0299129f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bdd0299129f0, replyNumber=0, likeNumber=62, createdTime=2022-02-26, rootId=0, userName=mashirong, userId=f13d475, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bdd0299129f0, moduleTitle=BMC Cancer：评估每周低剂量贝伐珠单抗联合方案治疗铂耐药卵巢癌患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bdd0299129f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1971903, encodeId=412119e1903de, content=<a href='/topic/show?id=f9c480e0860' target=_blank style='color:#2F92EE;'>#联合方案#</a>, objectTitle=Lancet Oncol：以PD-1/PD-L1抑制剂为基础的不同联合方案的不良事件发生情况, objectType=article, longId=215780, objectId=dc30215e8019, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc30215e8019, replyNumber=0, likeNumber=72, createdTime=2022-05-16, rootId=0, userName=mashirong, userId=f13d475, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc30215e8019, moduleTitle=Lancet Oncol：以PD-1/PD-L1抑制剂为基础的不同联合方案的不良事件发生情况, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc30215e8019)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1971906, encodeId=392719e1906c5, content=<a href='/topic/show?id=f9c480e0860' target=_blank style='color:#2F92EE;'>#联合方案#</a>, objectTitle=三药联合方案治疗晚期结直肠癌的效果, objectType=article, longId=220901, objectId=f96d2209012c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f96d2209012c, replyNumber=0, likeNumber=67, createdTime=2022-06-07, rootId=0, userName=mashirong, userId=f13d475, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f96d2209012c, moduleTitle=三药联合方案治疗晚期结直肠癌的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f96d2209012c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1971905, encodeId=fc8619e190540, content=<a href='/topic/show?id=f9c480e0860' target=_blank style='color:#2F92EE;'>#联合方案#</a>, objectTitle=J Clin Oncol：卡博替尼与阿特珠单抗的联合方案在晚期肾细胞癌中初露锋芒！, objectType=article, longId=216873, objectId=09412168e302, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=09412168e302, replyNumber=0, likeNumber=125, createdTime=2021-10-03, rootId=0, userName=mashirong, userId=f13d475, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=09412168e302, moduleTitle=J Clin Oncol：卡博替尼与阿特珠单抗的联合方案在晚期肾细胞癌中初露锋芒！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=09412168e302)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1971902, encodeId=1f3919e19023c, content=<a href='/topic/show?id=f9c480e0860' target=_blank style='color:#2F92EE;'>#联合方案#</a>, objectTitle=Lancet oncol：多种放化疗联合方案治疗局部晚期头颈癌的疗效对比, objectType=article, longId=210448, objectId=c74521044816, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c74521044816, replyNumber=0, likeNumber=86, createdTime=2021-10-06, rootId=0, userName=mashirong, userId=f13d475, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c74521044816, moduleTitle=Lancet oncol：多种放化疗联合方案治疗局部晚期头颈癌的疗效对比, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c74521044816)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1971904, encodeId=e98919e1904b7, content=<a href='/topic/show?id=f9c480e0860' target=_blank style='color:#2F92EE;'>#联合方案#</a>, objectTitle=Clin Cancer Res：遗憾！阿特珠单抗+镭-223联合方案未能给mCRPC患者带来额外的临床效益, objectType=article, longId=216703, objectId=fd7e216e0320, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd7e216e0320, replyNumber=0, likeNumber=83, createdTime=2022-04-16, rootId=0, userName=mashirong, userId=f13d475, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd7e216e0320, moduleTitle=Clin Cancer Res：遗憾！阿特珠单抗+镭-223联合方案未能给mCRPC患者带来额外的临床效益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd7e216e0320)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1971901, encodeId=057119e19010f, content=<a href='/topic/show?id=f9c480e0860' target=_blank style='color:#2F92EE;'>#联合方案#</a>, objectTitle=罗氏阿替利珠单抗+贝伐珠单抗联合方案在中国获批，用于一线治疗肝细胞癌, objectType=article, longId=202634, objectId=735d202634e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=735d202634e5, replyNumber=0, likeNumber=122, createdTime=2021-08-02, rootId=0, userName=mashirong, userId=f13d475, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=735d202634e5, moduleTitle=罗氏阿替利珠单抗+贝伐珠单抗联合方案在中国获批，用于一线治疗肝细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=735d202634e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1971900, encodeId=1d1119e1900bc, content=<a href='/topic/show?id=f9c480e0860' target=_blank style='color:#2F92EE;'>#联合方案#</a>, objectTitle=EB病毒相关肿瘤的治疗：nanatinostat和valganciclovir联合方案获FDA孤儿药称号, objectType=article, longId=196509, objectId=412c196509e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=412c196509e8, replyNumber=0, likeNumber=74, createdTime=2021-03-07, rootId=0, userName=mashirong, userId=f13d475, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=412c196509e8, moduleTitle=EB病毒相关肿瘤的治疗：nanatinostat和valganciclovir联合方案获FDA孤儿药称号, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=412c196509e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1971898, encodeId=49cc19e1898c4, content=<a href='/topic/show?id=f9c480e0860' target=_blank style='color:#2F92EE;'>#联合方案#</a>, objectTitle=【2019 ESMO】林榕波教授团队报道四药联合方案治疗晚期胃癌, objectType=article, longId=180680, objectId=779218068058, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=779218068058, replyNumber=0, likeNumber=106, createdTime=2020-04-01, rootId=0, userName=mashirong, userId=f13d475, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=779218068058, moduleTitle=【2019 ESMO】林榕波教授团队报道四药联合方案治疗晚期胃癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=779218068058)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1971899, encodeId=967c19e1899cc, content=<a href='/topic/show?id=f9c480e0860' target=_blank style='color:#2F92EE;'>#联合方案#</a>, objectTitle=李建勇教授：CLL/SLL新药“喷涌”，联合方案获益更多, objectType=article, longId=186205, objectId=93c618620524, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93c618620524, replyNumber=0, likeNumber=68, createdTime=2020-03-31, rootId=0, userName=mashirong, userId=f13d475, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93c618620524, moduleTitle=李建勇教授：CLL/SLL新药“喷涌”，联合方案获益更多, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=93c618620524)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1971894, encodeId=d0e319e18949c, content=<a href='/topic/show?id=f9c480e0860' target=_blank style='color:#2F92EE;'>#联合方案#</a>, objectTitle=CDK4/6抑制剂联合方案给HR+/HER2-乳腺癌患者带来的新希望, objectType=article, longId=167338, objectId=864316e338a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=864316e338a0, replyNumber=0, likeNumber=61, createdTime=2020-03-19, rootId=0, userName=mashirong, userId=f13d475, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=864316e338a0, moduleTitle=CDK4/6抑制剂联合方案给HR+/HER2-乳腺癌患者带来的新希望, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=864316e338a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1971893, encodeId=2de619e1893fe, content=<a href='/topic/show?id=f9c480e0860' target=_blank style='color:#2F92EE;'>#联合方案#</a>, objectTitle=BLOOD：基于伊布替尼的联合方案治疗复发/难治CNS淋巴瘤效果显著, objectType=article, longId=166158, objectId=fd4816615892, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd4816615892, replyNumber=0, likeNumber=42, createdTime=2020-04-10, rootId=0, userName=mashirong, userId=f13d475, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd4816615892, moduleTitle=BLOOD：基于伊布替尼的联合方案治疗复发/难治CNS淋巴瘤效果显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd4816615892)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1971897, encodeId=5e5219e189785, content=<a href='/topic/show?id=f9c480e0860' target=_blank style='color:#2F92EE;'>#联合方案#</a>, objectTitle=哌柏西利联合方案给继发性内分泌耐药的晚期HR+乳腺癌带来生存获益, objectType=article, longId=176484, objectId=f6861e6484d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f6861e6484d2, replyNumber=0, likeNumber=67, createdTime=2020-01-12, rootId=0, userName=mashirong, userId=f13d475, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f6861e6484d2, moduleTitle=哌柏西利联合方案给继发性内分泌耐药的晚期HR+乳腺癌带来生存获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f6861e6484d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1971895, encodeId=a33219e189575, content=<a href='/topic/show?id=f9c480e0860' target=_blank style='color:#2F92EE;'>#联合方案#</a>, objectTitle=ASCO 2019：奥希替尼单药和联合方案双双凸显一线治疗EGFR+NSCLC优势, objectType=article, longId=167944, objectId=04f516e94484, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04f516e94484, replyNumber=0, likeNumber=66, createdTime=2019-10-25, rootId=0, userName=mashirong, userId=f13d475, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04f516e94484, moduleTitle=ASCO 2019：奥希替尼单药和联合方案双双凸显一线治疗EGFR+NSCLC优势, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04f516e94484)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1971896, encodeId=d40d19e189668, content=<a href='/topic/show?id=f9c480e0860' target=_blank style='color:#2F92EE;'>#联合方案#</a>, objectTitle=哌柏西利联合方案为绝经前HR+晚期乳腺癌患者带来新希望！, objectType=article, longId=168153, objectId=1b2d1681532a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b2d1681532a, replyNumber=0, likeNumber=63, createdTime=2020-05-09, rootId=0, userName=mashirong, userId=f13d475, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b2d1681532a, moduleTitle=哌柏西利联合方案为绝经前HR+晚期乳腺癌患者带来新希望！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b2d1681532a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1971892, encodeId=e25419e189254, content=<a href='/topic/show?id=f9c480e0860' target=_blank style='color:#2F92EE;'>#联合方案#</a>, objectTitle=FDA批准：AbbVie与强生公司的伊布替尼作为CLL一线治疗的第一个非化疗联合方案, objectType=article, longId=159161, objectId=a1f815916100, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a1f815916100, replyNumber=0, likeNumber=67, createdTime=2019-05-29, rootId=0, userName=mashirong, userId=f13d475, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a1f815916100, moduleTitle=FDA批准：AbbVie与强生公司的伊布替尼作为CLL一线治疗的第一个非化疗联合方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a1f815916100)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

联合方案

2020-05-29

mashirong (审核中...)

前往app查看评论内容

#联合方案#

速览奥希耐药治疗策略和结果，几大联合方案不如专注新疗法？

2022-07-24

mashirong (审核中...)

前往app查看评论内容

#联合方案#

Clin Cancer Res：帕博西尼+氟维司群联合方案或可成为晚期乳腺癌的标准疗法

2022-11-04

mashirong (审核中...)

前往app查看评论内容

#联合方案#

BMC Cancer：评估每周低剂量贝伐珠单抗联合方案治疗铂耐药卵巢癌患者的疗效

2022-02-26

mashirong (审核中...)

前往app查看评论内容

#联合方案#

Lancet Oncol：以PD-1/PD-L1抑制剂为基础的不同联合方案的不良事件发生情况

2022-05-16

mashirong (审核中...)

前往app查看评论内容

#联合方案#

三药联合方案治疗晚期结直肠癌的效果

2022-06-07

mashirong (审核中...)

前往app查看评论内容

#联合方案#

J Clin Oncol：卡博替尼与阿特珠单抗的联合方案在晚期肾细胞癌中初露锋芒！

2021-10-03

mashirong (审核中...)

前往app查看评论内容

#联合方案#

Lancet oncol：多种放化疗联合方案治疗局部晚期头颈癌的疗效对比

2021-10-06

mashirong (审核中...)

前往app查看评论内容

#联合方案#

Clin Cancer Res：遗憾！阿特珠单抗+镭-223联合方案未能给mCRPC患者带来额外的临床效益

2022-04-16

mashirong (审核中...)

前往app查看评论内容

#联合方案#

罗氏阿替利珠单抗+贝伐珠单抗联合方案在中国获批，用于一线治疗肝细胞癌

2021-08-02

mashirong (审核中...)

前往app查看评论内容

#联合方案#

EB病毒相关肿瘤的治疗：nanatinostat和valganciclovir联合方案获FDA孤儿药称号

2021-03-07

mashirong (审核中...)

前往app查看评论内容

#联合方案#

【2019 ESMO】林榕波教授团队报道四药联合方案治疗晚期胃癌

2020-04-01

mashirong (审核中...)

前往app查看评论内容

#联合方案#

李建勇教授：CLL/SLL新药“喷涌”，联合方案获益更多

2020-03-31

mashirong (审核中...)

前往app查看评论内容

#联合方案#

CDK4/6抑制剂联合方案给HR+/HER2-乳腺癌患者带来的新希望

2020-03-19

mashirong (审核中...)

前往app查看评论内容

#联合方案#

BLOOD：基于伊布替尼的联合方案治疗复发/难治CNS淋巴瘤效果显著

2020-04-10

mashirong (审核中...)

前往app查看评论内容

#联合方案#

哌柏西利联合方案给继发性内分泌耐药的晚期HR+乳腺癌带来生存获益

2020-01-12

mashirong (审核中...)

前往app查看评论内容

#联合方案#

ASCO 2019：奥希替尼单药和联合方案双双凸显一线治疗EGFR+NSCLC优势

2019-10-25

mashirong (审核中...)

前往app查看评论内容

#联合方案#

哌柏西利联合方案为绝经前HR+晚期乳腺癌患者带来新希望！

2020-05-09

mashirong (审核中...)

前往app查看评论内容

#联合方案#

FDA批准：AbbVie与强生公司的伊布替尼作为CLL一线治疗的第一个非化疗联合方案

2019-05-29

科室
- - 订阅+
  - 更多科室
工具
服务